NGL Fine Chem Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 31 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.1K Cr
Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies. - Volume growth is stable with demand recovery confirmed over the last three quarters, providing confidence for maintaining or improving current run rates. - New plant expansions are expected to add up to Rs. FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth. - Volume-led growth and capacity expansions are key growth drivers. - New plant Phase I is operational; Phase II commissioning expected early Q2 FY27, commercial production H2 FY27. - Partial price pass-through achieved; further margin improvement expected as commodity cost pressures stabilize. - EBITDA margin guidance remains 15%-18%; new regulated market segments could add 3%-5% margin premium. - Regulated market sales to start contributing meaningfully from FY28 onwards. - Peak revenue potential from new expansion estimated at Rs.
From NGL Fine Chem's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,948
Market Cap
₹2.1K Cr
P/E Ratio
42.3
Revenue Rank
Margin Rank
How does NGL Fine Chem rank in Pharmaceuticals & Biotechnology?
Compare NGL Fine Chem against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
NGL Fine Chem — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹145 Cr, net profit ₹11 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies.
- →Volume growth is stable with demand recovery confirmed over the last three quarters, providing confidence for maintaining or improving current run rates.
- →New plant expansions are expected to add up to Rs. 350 crores in turnover over the next 3-4 years.
- →Regulated market sales (Europe starting FY27, US from FY28) will contribute meaningfully from FY28 onwards, though peak contributions are still to be crystallized.
- →The company aims to stabilize at a quarterly run rate of approx. Rs. 150 crore, with potential to exceed it over time.
- →Continued addition of 9-10 new products annually supports diversified growth.
- →Uptake in Latin America, Africa, and Southeast Asia markets further supports volume increases.
- →Organic growth plus capacity expansions position the company well for sustained revenue and volume growth over the next 2-4 years.
📈 Profitability & Margins
Rank 3- →FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth.
- →Volume-led growth and capacity expansions are key growth drivers.
- →New plant Phase I is operational; Phase II commissioning expected early Q2 FY27, commercial production H2 FY27.
- →Partial price pass-through achieved; further margin improvement expected as commodity cost pressures stabilize.
- →EBITDA margin guidance remains 15%-18%; new regulated market segments could add 3%-5% margin premium.
- →Regulated market sales to start contributing meaningfully from FY28 onwards.
- →Peak revenue potential from new expansion estimated at Rs. 350 crores over 3-4 years.
- →Overall, maintaining cautious optimism with stabilized quarterly run rate targets around Rs.150 crore and anticipation of continued broad-based demand and customer additions.
- →Management expects steady revenue and margin growth aligned with capacity scaling and market expansion over next 2-3 years.
🏗️ Capital Expenditure Plans
Yes- →Total planned CAPEX for the ongoing expansion program is ₹210 crores, with ₹182.75 crores invested up to Q4 FY26.
- →Phase II Greenfield expansion at Tarapur faced delays due to gas and labor shortages; commissioning rescheduled from Q1 FY27 to early Q2 FY27.
- →Commercial production for Phase II is expected to start from H2 FY27, as previously guided.
- →Post project completion, annual CAPEX is expected to be around ₹15-20 crores.
- →No additional large-scale CAPEX currently planned beyond this expansion.
- →Management is financing the cost increase internally, without additional borrowing.
- →Peak utilization of new capacity is anticipated over the next 3-4 years.
- →No forward-looking numbers shared on future strategic investments or dividend plans; management remains cautious on projections.
💰 Fundraising & Capital Structure
No- →There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript.
- →The company has completed CAPEX of around Rs. 182 crores for capacity expansion in Q4, with total project CAPEX estimated at about Rs. 210 crores.
- →Going forward, annual CAPEX is expected to be around Rs. 15 to 20 crores.
- →The management indicated funding the entire increase in costs internally without additional borrowing.
- →Debt outstanding is approximately Rs. 100 crores currently.
- →Management has not provided details on future capital allocation plans including dividends or buybacks but is focused on repaying debt and supporting ongoing CAPEX from internal cash flows.
- →No announcements were made regarding equity fundraising or fresh debt issuance during the call.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were NGL Fine Chem Q4 FY26 results?
Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies. - Volume growth is stable with demand recovery confirmed over the last three quarters, providing confidence for maintaining or improving current run rates. - New plant expansions are expected to add up to Rs. FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth. - Volume-led growth and capacity expansions are key growth drivers. - New plant Phase I is operational; Phase II commissioning expected early Q2 FY27, commercial production H2 FY27. - Partial price pass-through achieved; further margin improvement expected as commodity cost pressures stabilize. - EBITDA margin guidance remains 15%-18%; new regulated market segments could add 3%-5% margin premium. - Regulated market sales to start contributing meaningfully from FY28 onwards. - Peak revenue potential from new expansion estimated at Rs.
What is NGL Fine Chem share price analysis?
NGL Fine Chem currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 42.3 with a market cap of ₹2,135 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem planning capital expenditure?
Total planned CAPEX for the ongoing expansion program is ₹210 crores, with ₹182.75 crores invested up to Q4 FY26.
Keep NGL Fine Chem on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.